alexa Highly specific targeting of the TMPRSS2 ERG fusion gene using liposomal nanovectors


Diagnostic Pathology: Open Access

Author(s): Shao L, Tekedereli I, Wang J, Yuca E, Tsang S

Abstract Share this page

PURPOSE: The TMPRSS2/ERG (T/E) fusion gene is present in half of all prostate cancer tumors. Fusion of the oncogenic ERG gene with the androgen-regulated TMPRSS2 gene promoter results in expression of fusion mRNAs in prostate cancer cells. The junction of theTMPRSS2- and ERG-derived portions of the fusion mRNA constitutes a cancer-specific target in cells containing the T/E fusion gene. Targeting the most common alternatively spliced fusion gene mRNA junctional isoforms in vivo using siRNAs in liposomal nanovectors may potentially be a novel, low-toxicity treatment for prostate cancer.

EXPERIMENTAL DESIGN: We designed and optimized siRNAs targeting the two most common T/E fusion gene mRNA junctional isoforms (type III or type VI). Specificity of siRNAs was assessed by transient co-transfection in vitro. To test their ability to inhibit growth of prostate cancer cells expressing these fusion gene isoforms in vivo, specific siRNAs in liposomal nanovectors were used to treat mice bearing orthotopic or subcutaneous xenograft tumors expressing the targeted fusion isoforms.

RESULTS: The targeting siRNAs were both potent and highly specific in vitro. In vivo they significantly inhibited tumor growth. The degree of growth inhibition was variable and was correlated with the extent of fusion gene knockdown. The growth inhibition was associated with marked inhibition of angiogenesis and, to a lesser degree, proliferation and a marked increase in apoptosis of tumor cells. No toxicity was observed.

CONCLUSIONS: Targeting the T/E fusion junction in vivo with specific siRNAs delivered via liposomal nanovectors is a promising therapy for men with prostate cancer.

This article was published in Clinical Cancer Research and referenced in Diagnostic Pathology: Open Access

Relevant Expert PPTs

Relevant Speaker PPTs

  • Jee Shum
    PRS Co-resident Objective Measure of IHC Stain Performance for Process QC and Diagnostic Aid
    PPT Version | PDF Version
  • Manish Kumar
    GOD’s diagnostic tool is the mathematics and prescription is physics
    PPT Version | PDF Version
  • Tomoi Koide
    Generalization of framework of analytic mechanics and unified description of quantum and classical physics
    PDF Version
  • Michael M. Ling
    Rapid Molecular Diagnostics of HIV-1 RNA from Plasma
    PPT Version | PDF Version
  • Wayne Grant Carter
    PPT Version | PDF Version
  • Vicente Marco
    Changes in breast cancer pathology reports after second opinion
    PPT Version | PDF Version
  • Jan Voskuil
    How antibodies can prevent medical progress and how they can be great tools?
    PPT Version | PDF Version
  • Monray Edward Williams
    Molecular validation of putative antimicrobial peptides for improved Human Immunodeficiency Virus diagnostics via HIV protein p24
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Michelle Tseng
    Innovative diagnostic approach in primary immune deficiencies
    PPT Version | PDF Version
  • Omar Ahmad Abu Suliman
    Diagnostic and therapeutic challenges in IgG4-related disease in the Sphenoid sinus
    PPT Version | PDF Version
  • Federico Cattin
    Breast cancer: A comparison among different diagnostic and therapeutic protocols
    PPT Version | PDF Version
  • Lei Huo
    Diagnostic biomarkers in metastatic breast cancer
    PPT Version | PDF Version
  • Malvika Chaudhary
    National partnerships in Asian countries to collaborate with Global Program Plantwise as diagnostic and advisory services in agriculture
    PPT Version | PDF Version
  • S K Dhattarwal
    PPT Version | PDF Version
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version